1,211 results on '"Galimberti, S"'
Search Results
152. Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses
153. Atypical APL including multiple translocations and abnormal response to micronuclei induction test
154. Expression of multidrug resistance (mdr) gene(s) in primary lymphoid organs of chicken immune system during embryonic development
155. Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor
156. Granulocytic sarcoma and subsequent acute leukemia recurrence with different biologic characteristics 5 years after allogeneic bone marrow transplantation for acute myeloid leukemia
157. Loss of donor T-cell chimerism in the setting of non-myeloablative stem cell transplant approached with restoration of immunosuppression one dose of fludarabine and subsequent DLI
158. MALDI-MSI as a Complementary Diagnostic Tool in Cytopathology: A Pilot Study for the Characterization of Thyroid Nodules
159. Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical study
160. Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study
161. Prevalence and timing of tracheostomy in traumatic brain injured patients: a secondary analysis from the CENTER-TBI study
162. Hybrid Imaging and Radionuclide Therapy in Hemato-oncology
163. outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline
164. The management of haemoglobin interference for the MALDI-MSI proteomics analysis of thyroid fine needle aspiration biopsies
165. Use of Shear Wave Elastography in the Sonographic Triage of Thyroid Nodules: Feasibility Study in a Series of Lesions Already Selected for Fine Needle Aspiration
166. Feasibility Study for the MALDI-MSI Analysis of Thyroid Fine Needle Aspiration Biopsies: Evaluating the Morphological and Proteomic Stability Over Time
167. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
168. The evolving landscape of diagnostic pathology: a step towards the integration of MALDI-MSI for the routine diagnosis of thyroid fine needle aspiration biopsies
169. Results of a Multicentre, Randomized, Controlled Open-Label Study on the Use of Anti-T-Lymphocyte Globulin (ATLG) and Rituximab for Immunomodulation of Graft-Versus-Host Disease (GvHD) and Graft Failure (GF) in Patients with Non-Malignant Disorders.
170. Identification of aberrant serum IgG glycoforms in Idiopathic membranous nephropathy
171. New approaches for the validation of a highly skewed surrogate for a survival endpoint
172. The validation of a highly skewed surrogate for a survival endpoint: new approaches
173. HaraliCU: GPU-Powered Haralick Feature Extraction on Medical Images Exploiting the Full Dynamics of Gray-Scale Levels
174. Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib
175. A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings
176. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis
177. Unusual morphology in a case of large granular cell leukemia
178. Treatment of childhood Wilms' tumor without radiotherapy in Nicaragua
179. MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES
180. POLYMORPHISMS IN MULTIDRUG RESISTANCE TRANSPORTER GENES MAY AFFECT THE LOSS OF MOLECULAR RESPONSE TO NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS
181. S123 SETD2 LOSS OF FUNCTION IS A RECURRENT EVENT IN ADVANCED-PHASE CHRONIC MYELOID LEUKEMIA INDUCED BY POST-TRANSLATIONAL MECHANISMS THAT CAN BE THERAPEUTICALLY TARGETED
182. PB2194 DE-REGULATION OF MIRNAS DURING TREATMENT OF PATIENTS AFFECTED BY MYELOFIBROSIS WITH RUXOLITINIB
183. PF172 PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
184. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.
185. PS1010 IDH2 GENE MUTATIONS DETECTION IN ACUTE MYELOID LEUKEMIA: SCREENING AND MRD MONITORING BY “DROP-OFF” DDPCR
186. PF420 RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON PRO‐ATHEROTHROMBOTIC EFFECT INDUCED BY TYROSINE‐KINASE INHIBITORS FOR FIRST‐LINE TREATMENT OF CML PTS (KIARO TRIAL)
187. Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia
188. Efficacy and safety of extracranial vein angioplasty in multiple sclerosis: A randomized clinical trial
189. Proprotein convertase 7 rs236918 associated with liver fibrosis in Italian patients with HFE-related hemochromatosis
190. IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA
191. ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY
192. CLONOTYPE AND MUTATIONAL PATTERN IN TCRGD LARGE GRANULAR LYMPHOCYTE LEUKEMIA
193. Persistence of Residual Circulating CD26+Leukemia Stem Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission
194. TCR gamma delta Large Granular Lymphocyte Leukemia (LGLL) Displays Features between CD8+and CD4+TCR alpha beta LGLL
195. Second Generation Tyrosine Kinase Inhibitors (2G-TKI) in the Frontline Treatment of Elderly Patients with Chronic Myeloid Leukemia
196. TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EOSINOPHILOIA IN EGPA FROM HES
197. LONG-TERM FOLLOW-UP IN VERY ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB FRONTLINE
198. EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES)
199. TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES
200. Observational Study of CML Italian Patients Who Discontinued TKIs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.